CAS 31431-39-7 Mebendazole - Analytical Products / Alfa Chemistry

CAT	APS31431397
CAS	31431-39-7
Structure
MDL Number	MFCD00057872
Synonyms	5-Benzoyl-2-benzimidazolecarbamic acid methyl ester, R 17635, NSC 184849, Zhihuanqing, Vermicidin, (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester, 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI), Telmin, Vermirax, Bantenol, Mebex,Carbamic acid, N-(6-benzoyl-1H-benzimidazol-2-yl)-, methyl ester, Pantelmin, Methyl 5-benzoyl-2-benzimidazolylcarbamate, Besantin, Methyl 5-benzoyl-2-benzimidazolecarbamate, Noverme, Lomper, Vermox, Ovitelmin, Equivurm Plus, Mebenvet, Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI), Verpanyl, Mebendazole
IUPAC Name	methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate
Molecular Weight	295.29
Molecular Formula	C16H13N3O3
Canonical SMILES	COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3
InChI	InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
InChI Key	OPXLLQIJSORQAM-UHFFFAOYSA-N
REAXYS Number	759809

Description	United States Pharmacopeia (USP) Reference Standard
Accurate Mass	295.0957
Form	neat
Format	Neat
Size	200MG

* Products or Services Interested: Mebendazole (31431-39-7)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS31431397-1	100MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: British Pharmacopoeia	Inquiry
APS31431397-2	100MG	Room Temperature	+20°C	Subcategory: EU Methods, Pharmaceutical and veterinary compounds and metabolites	Inquiry
APS31431397-3	20MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: European Pharmacopoeia (Ph. Eur.)	Inquiry
APS31431397-4	250MG			API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: International Pharmacopoeia	Inquiry
APS31431397-5	250MG	Room Temperature	+5°C	API Family: Matrix - API Family Mebendazole; Product Type: API; Subcategory: Mikromol, API standards, Antibiotics	Inquiry

Case Study

Mebendazole as a Potent Agent for Anti-AML Therapy: Mechanisms and Preclinical Evaluation

Yang, Wei, et al. Journal of Advanced Research (2025).

This study investigates the potential of mebendazole (MBD), a widely used anthelmintic drug, as an anti-leukemic agent for acute myeloid leukemia (AML). Despite advancements in AML treatment, a significant number of patients remain refractory or at high risk of recurrence, underscoring the need for novel therapeutic approaches. Mebendazole was identified through a small molecule drug screen for its ability to induce inflammatory cell death in AML cells.
In vitro experiments demonstrated that MBD inhibits the cell cycle at the G2/M phase by targeting tubulin α1A (TUBA1A), leading to cell death via ZBP-1 mediated PANoptosis. Further analysis, including western blotting, RNA-seq, and molecular docking, confirmed the inhibitory effects on AML cell invasion. In vivo studies using xenograft mouse models of AML showed that MBD significantly inhibits tumor growth while causing minimal toxicity to normal tissues.
The findings highlight MBD as a promising low-toxicity, cost-effective candidate for the treatment of AML. Moreover, TUBA1A emerges as a potential novel therapeutic target for tumors with abnormal TUBA1A expression. This study suggests that MBD could offer a new treatment avenue for AML patients, with strong preclinical evidence supporting its clinical translational potential.

Mebendazole-Loaded Nanochitosan and Zinc Oxide Nanoparticles for Enhanced Antiparasitic Delivery

Henaish, Aya M., et al. Inorganic Chemistry Communications 173 (2025): 113843.

This study explores the formulation of a novel medication system for mebendazole (MBZ), an antiparasitic agent, using a nanocomposite approach with nanochitosan (Cs) and zinc oxide nanoparticles (ZnO NPs). The aim is to enhance the drug delivery and efficacy of MBZ through the self-assembly of the drug with the surface of Cs and ZnO nanoparticles.
The Cs NPs were first synthesized, combined with MBZ, and subjected to ultrasonication to achieve a uniform dispersion in deionized water. Subsequently, ZnO NPs were prepared using a precipitation method, followed by calcination at 450 °C to form well-defined nanoparticles. These ZnO NPs were incorporated into the Cs@MBZ nanocomposite, and the resulting solution was agitated overnight to ensure homogeneity.
The Cs-MBZ@ZnO nanocomposite was characterized by scanning electron microscopy (SEM) and X-ray diffraction (XRD) to confirm the structural integrity and composition of the particles. The SEM micrographs provided insight into the nanoparticle morphology, while the XRD patterns revealed the crystalline structure of the ZnO nanoparticles within the composite.
This study demonstrates the potential of MBZ-loaded Cs@ZnO nanocomposites as a promising delivery system for improved antiparasitic efficacy, providing a foundation for future development of nanomedicine in parasitic infections.

Mebendazole as a Corrosion Inhibitor for 5Cr Pipeline Steel in HCl Medium

Han, Fengshuang, et al. International Journal of Electrochemical Science 18.10 (2023): 100319.

This study investigates the effectiveness of mebendazole (MBD) as a corrosion inhibitor for 5Cr pipeline steel in hydrochloric acid (HCl) medium. Electrochemical tests reveal that mebendazole significantly prevents the corrosion of 5Cr steel, with inhibition efficiency (η) improving as the concentration of mebendazole increases. The highest inhibition efficiency achieved was 94.4% at optimal concentrations.
The electrochemical impedance spectroscopy (EIS) and immersion weight loss experiments corroborate these findings, with scanning electron microscopy (SEM) analysis confirming the protective effect on the metal surface. Theoretical calculations show that protonated mebendazole molecules, both in solvated and unsolvated states, exhibit lower energy gaps and higher dipole moments, facilitating efficient adsorption on the steel surface.
The polarization curves, obtained using potentiodynamic polarization (PDP) analysis, demonstrate a significant decrease in corrosion current (icorr) with increasing mebendazole concentration. The η value reached 86.3% at 0.2 mM, surpassing 90% at concentrations above 2 mM, and achieving a peak value of 93.5% at 5 mM.
These results highlight mebendazole as a promising corrosion inhibitor for steel in acidic environments, offering both theoretical and practical insights into its mechanism of action.